Proficio Capital Partners LLC Purchases New Position in Edwards Lifesciences Co. (NYSE:EW)

Proficio Capital Partners LLC purchased a new stake in Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 114,228 shares of the medical research company’s stock, valued at approximately $8,456,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Versor Investments LP grew its stake in shares of Edwards Lifesciences by 102.5% during the third quarter. Versor Investments LP now owns 4,455 shares of the medical research company’s stock valued at $294,000 after acquiring an additional 2,255 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Edwards Lifesciences during the third quarter valued at about $481,000. MQS Management LLC acquired a new stake in shares of Edwards Lifesciences during the third quarter valued at about $245,000. Oppenheimer & Co. Inc. grew its stake in shares of Edwards Lifesciences by 3.9% during the third quarter. Oppenheimer & Co. Inc. now owns 38,186 shares of the medical research company’s stock valued at $2,520,000 after acquiring an additional 1,441 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in Edwards Lifesciences by 8.9% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 18,140 shares of the medical research company’s stock worth $1,197,000 after purchasing an additional 1,480 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,803 shares of company stock worth $3,900,976. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

NYSE EW opened at $69.37 on Friday. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $40.78 billion, a PE ratio of 9.95, a P/E/G ratio of 4.82 and a beta of 1.12. The company’s 50 day simple moving average is $71.74 and its 200 day simple moving average is $70.33.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on EW. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. The Goldman Sachs Group lifted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Truist Financial reiterated a “hold” rating and issued a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Evercore ISI decreased their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.